Withdraws three approved ANDAs after FDA notifies company that the agency would begin proceedings to withdraw approval of the applications. The announcement of the withdrawal in the Feb. 21 Federal Register states that FDA "became aware of untrue statements, discrepancies, and omissions" relating to the ANDAs for prochlorperazine maleate tabs, 5 mg, 10 mg, and 25 mg. All three dosage strengths were part of a five-product recall by Duramed in January ("The Pink Sheet" Jan. 21, T&G-11).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth